Literature DB >> 23041131

Fast dissolving eutectic compositions of curcumin.

N Rajesh Goud1, Kuthuru Suresh, Palash Sanphui, Ashwini Nangia.   

Abstract

The bioactive herbal ingredient curcumin was screened with pharmaceutically acceptable coformers to discover solid-state forms of high solubility. Mechano-chemical grinding of curcumin with cocrystal formers in a fixed stoichiometry ratio resulted in binary eutectic compositions of curcumin-coformer with nicotinamide (1:2), ferulic acid (1:1), hydroquinone (1:1), p-hydroxybenzoic acid (1:1), and l-tartaric acid (1:1). The eutectic nature of the product crystalline solids was established by differential scanning calorimetry, and the absence of hydrogen-bonded crystalline phases such as cocrystals/salts was ascertained by powder X-ray diffraction, IR-Raman, and solid-state NMR spectroscopy. The best case of CUR-NAM eutectic exhibits 10-fold faster IDR and 6-times higher AUC compared to crystalline curcumin.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041131     DOI: 10.1016/j.ijpharm.2012.09.045

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Investigating Cocrystallization of Carbamazepine with Structurally Compatible Coformers: New Cocrystal and Eutectic Phases with Enhanced Dissolution.

Authors:  Indumathi Sathisaran; Sameer Vishvanath Dalvi
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

Review 2.  Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium.

Authors:  Indumathi Sathisaran; Sameer Vishvanath Dalvi
Journal:  Pharmaceutics       Date:  2018-07-31       Impact factor: 6.321

3.  Curcumin and n-acetylcysteine cocrystal produced with supercritical solvent: characterization, solubility, and preclinical evaluation of antinociceptive and anti-inflammatory activities.

Authors:  Alessandro R Paulazzi; Bianca O Alves; Gabriela A L Zilli; Aline E Dos Santos; Fernanda Petry; Krissie D Soares; Letícia J Danielli; Jefferson Pedroso; Miriam A Apel; Gean Pablo S Aguiar; Anna M Siebel; J Vladimir Oliveira; Liz Girardi Müller
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

4.  Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr-/-Mice.

Authors:  Shamuha Bahetibieke; Sakib M Moinuddin; Asiya Baiyisaiti; Xiaoang Liu; Jie Zhang; Guomin Liu; Qin Shi; Ankang Peng; Jun Tao; Chang Di; Ting Cai; Rong Qi
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

5.  Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations.

Authors:  Agata Górniak; Adrianna Złocińska; Mateusz Trojan; Adrianna Pęcak; Bożena Karolewicz
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

6.  Curcumin-Artemisinin Coamorphous Solid: Xenograft Model Preclinical Study.

Authors:  M K Chaitanya Mannava; Kuthuru Suresh; Manish Kumar Bommaka; Durga Bhavani Konga; Ashwini Nangia
Journal:  Pharmaceutics       Date:  2018-01-09       Impact factor: 6.321

Review 7.  Therapeutic Deep Eutectic Systems towards the Treatment of Tuberculosis and Colorectal Cancer: Opportunities and Challenges.

Authors:  Filipe Oliveira; Filipa Santos; Ana Rita C Duarte
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

Review 8.  Natural deep eutectic solvents in phytonutrient extraction and other applications.

Authors:  Dan Li
Journal:  Front Plant Sci       Date:  2022-09-21       Impact factor: 6.627

Review 9.  Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering.

Authors:  Danyingzi Guan; Bianfei Xuan; Chengguang Wang; Ruitao Long; Yaqin Jiang; Lina Mao; Jinbing Kang; Ziwen Wang; Shing Fung Chow; Qun Zhou
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.